Also because of a lack of disease specific therapeutic strategies in the last decades we investigated a new possible strategy to target the SEC62 oncogene that is highly overexpressed in 86% of all HNSCC patients (Wemmert et al., 2016). Here, SEC62 is linked to head and neck squamous cell carcinoma.